Clinical Trial Update: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults [Phase 4]

View source ↗

Summary

Phase 4 pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Diseases

Drugs mentioned

• ICOSAPENT ETHYL (icosapent ethyl)

Snippet

Sponsor: Kaiser Permanente | Conditions: Covid19, Atherosclerosis | Phase 4 | Status: TERMINATED